Results 31 to 40 of about 8,252,790 (324)

A study of new drug approval pattern of a Southeast Asian developed country from 2017 to 2021

open access: yesNational Journal of Physiology, Pharmacy and Pharmacology, 2023
Background: The pattern of new drug approval is changing across the world as shown by the study using Center for Drug Evaluation and Research and European Medicines Agency data in US and UK with more drug approval for anti-cancer and immunomodulator ...
Nilesh Chavda   +3 more
doaj   +1 more source

Regulatory Approval process for marketing drug in Japan

open access: yesInternational Journal of Research in Pharmaceutical Sciences, 2021
For the development of new drug, it requires a greater amount of research work in chemistry, Manufacturing, control, Preclinical and clinical trials. The drug approval process in all regulatory market carrying responsibilities on multiple factors such as
Uma Maheshwari A, Kamaraj R
doaj   +1 more source

Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis

open access: yesClinical pharmacology and therapy, 2020
The Pharmaceuticals and Medical Devices Agency (PMDA) has approved hundreds of new drugs in recent years. We retrospectively analyzed the new drugs approved in Japan from 2008 to 2019, and identify the first‐in‐world approvals and clarify the current ...
Mototsugu Tanaka   +10 more
semanticscholar   +1 more source

Product Complexity and Strategic Alliance on Drug Approval

open access: yesAmerican Business Review, 2021
Management of the business-government relationship is critical for firm performance in regulated industries. In this paper, we predict a U-shaped relationship between product complexity and the time to approval by the US Food and Drug Administration (FDA)
Taoyong Su   +3 more
doaj   +1 more source

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?

open access: yesCancer Management and Research, 2021
Michael Patrick Lux, 1 Oriana Ciani, 2 William CN Dunlop, 3 Andrea Ferris, 4 Michael Friedlander 5 1Department of Gynecology and Obstetrics, Frauenklinik St. Louise Paderborn, St. Josefs-Krankenhaus Salzkotten, Frauen- und Kinderklinik St.
Lux MP   +4 more
doaj  

Regulatory reliance pathways during health emergencies: enabling timely authorizations for COVID-19 vaccines in Latin America

open access: yesRevista Panamericana de Salud Pública, 2022
Objectives. To map the timing and nature of regulatory reliance pathways used to authorize COVID-19 vaccines in Latin America. Methods. An observational study was conducted assessing the characteristics of all COVID-19 vaccine authorizations in Latin ...
Ivar T. van der Zee   +3 more
doaj   +1 more source

Pragmatic clinical trials in the context of regulation of medicines

open access: yesUpsala Journal of Medical Sciences, 2019
The pragmatic clinical trial addresses scientific questions in a setting close to routine clinical practice and sometimes using routinely collected data.
Rolf Gedeborg   +3 more
doaj   +1 more source

Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics

open access: yesJACC: Basic to Translational Science, 2017
Eroom’s law (Moore’s law spelled backwards), describes adverse trends towards declining innovation and rising costs of drug development over the last several decades.
Gail A. Van Norman, MD
doaj   +1 more source

Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.

open access: yesJAMA Oncology, 2019
Importance To date, an empirical evaluation of the quality of control arms in randomized clinical trials (RCTs) leading to anticancer drug approvals by the US Food and Drug Administration (FDA) has not been undertaken.
Talal Hilal, M. Sonbol, V. Prasad
semanticscholar   +1 more source

Pharmacists’ Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation

open access: yesPharmacy, 2022
The “breakthrough therapy” designation (BTD) is a recent mechanism implemented by the United States Food and Drug Administration (FDA) to expedite access to drugs that address unmet needs.
Megan C. Herink   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy